Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The broad objective of this investigation is to assess the safety and efficacy of oral therapy with dexmedetomidine for the induction and maintenance of restful sleep.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Age between 18-50

• Native English speaking

• ASA physical status classification P1 and P2 (stable chronic condition)

• Normal body habitus.

Exclusion Criteria:

• Abnormal sleep habits

• Sleeping less than 5 hours each night

• Going to sleep before 9:00 PM or after 2:00 AM on a regular basis

• Waking up before 5:00 AM or after 10:00 AM on a regular basis.

• Takes medication that alters sleep, cognitive function, or both. -Has a history of a known neurological or psychiatric problem.

• Younger than 18 or older than 50 years of age.

• Known or suspected sleep disorder(s).